Skip to main content

Advertisement

Table 3 Relationships between clinicopathological characteristics and pathological response evaluated by JGCA-TRG system

From: Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China

Characteristics Total cases (n = 192), no. (%) JGCA -TRG P value
3 (n = 11), no. (%) 2 (n = 63), no. (%) 1b (n = 45), no. (%) 1a (n = 33), no. (%) 0 (n = 40), no. (%)
Gender        0.097
 Male 139 (72.4) 10 (7.2) 48 (34.5) 30 (21.6) 19 (13.7) 32 (23)  
 Female 53 (27.6) 1 (1.9) 15 (28.3) 15 (28.3) 14 (26.4) 8 (15.1)  
Age        0.711
 < 55y 89 (46.4) 6 (6.7) 26 (29.2) 24 (27) 16 (18) 17 (19.1)  
 ≥ 55y 103 (53.6) 5 (4.9) 37 (35.9) 21 (20.4) 17 (16.5) 23 (22.3)  
Location        0.287
 Esophagogastric junction 44 (22.9) 1 (2.3) 12 (27.3) 10 (22.7) 10 (22.7) 11 (25)  
 Proximal gastric 71 (37) 7 (9.9) 23 (32.4) 15 (21.1) 8 (11.3) 18 (25.4)  
 Distal gastric 77 (40.1) 3 (3.9) 28 (36.4) 20 (26) 15 (19.5) 11 (14.3)  
Maximal diameter of tumor bed        <0.001
 < 4.5 cm 108 (56.2) 9 (8.3) 40 (37) 27 (25) 17 (15.7) 15 (13.9)  
 4.5–8 cm 64 (33.3) 1 (1.6) 21 (32.8) 14 (21.9) 12 (18.8) 16 (25)  
 > 8 cm 20 (10.4) 1 (5) 2 (10) 4 (20) 4 (20) 9 (45)  
Histological differentiation        0.060
 Well-moderate 45 (23.4) 4 (8.9) 21 (46.7) 10 (22.2) 6 (13.3) 4 (8.9)  
 Poor 147 (76.6) 7 (4.8) 42 (28.6) 35 (23.8) 27 (18.4) 36 (24.5)  
Laurén classification        
 Intestinal 77 (40.1) 4 (5.2) 29 (37.7) 18 (23.4) 11 (14.3) 15 (19.5)  
 Diffuse 73 (38) 7 (9.6) 20 (27.4) 16 (21.9) 16 (21.9) 14 (19.2)  
 Mixed 42 (21.9) 0 (0) 14 (33.3) 11 (26.2) 6 (14.3) 11 (26.2)  
LVI        <0.001
 Negative 94 (49) 11 (11.7) 46 (48.9) 19 (20.2) 8 (8.5) 10 (10.6)  
 Positive 98 (51) 0 (0) 17 (17.3) 26 (26.5) 25 (25.5) 30 (30.6)  
PNI        <0.001
 Negative 76 (39.6) 11 (14.5) 35 (46.1) 14 (18.4) 9 (11.8) 7 (9.2)  
 Positive 116 (60.4) 0 (0) 28 (24.1) 31 (26.7) 24 (20.7) 33 (28.4)  
AJCC ypT category        <0.001
 0 11 (5.7) 11 (100) 0 (0) 0 (0) 0 (0) 0 (0)  
 1 20 (10.4) 0 (0) 17 (85) 1 (5) 2 (10) 0 (0)  
 2 23 (12) 0 (0) 11 (47.8) 6 (26.1) 6 (26.1) 0 (0)  
 3 57 (29.7) 0 (0) 24 (42.1) 16 (28.1) 8 (14) 9 (15.8)  
 4 81 (42.2) 0 (0) 11 (13.6) 22 (27.2) 17 (21) 31 (38.3)  
AJCC ypN category        <0.001
 0 55 (28.6) 9 (16.4) 30 (54.5) 5 (9.1) 5 (9.1) 6 (10.9)  
 1 36 (18.8) 0 (0) 13 (26) 11 (30.6) 5 (13.9) 7 (19.4)  
 2 50 (26) 0 (0) 13 (26) 21 (42) 11 (22) 5 (10)  
 3 51 (26.6) 2 (3.9) 7 (13.7) 8 (15.7) 12 (23.5) 22 (43.1)  
AJCC stage        <0.001
 0 9 (4.7) 9 (100) 0 (0) 0 (0) 0 (0) 0 (0)  
 1 24 (12.5) 0 (0) 21 (87.5) 1 (4.2) 1 (4.2) 1 (4.2)  
 2 53 (27.6) 2 (3.8) 20 (37.7) 12 (22.6) 9 (17) 10 (18.9)  
 3 106 (55.2) 0 (0) 22 (20.8) 32 (30.2) 23 (21.7) 29 (27.4)  
R0 resection        0.046
 Yes 159 (82.8) 11 (6.9) 55 (34.6) 40 (25.2) 24 (15.1) 29 (18.2)  
 No 33 (17.2) 0 (0) 8 (24.2) 5 (15.2) 9 (27.3) 11 (33.3)  
Adjuvant chemotherapy        0.676
 Not received 59 (30.7) 3 (5.1) 16 (27.1) 13 (22) 12 (20.3) 15 (25.4)  
 Received 133 (69.3) 8 (6) 47 (35.3) 32 (24.1) 21 (15.8) 25 (18.8)